Anti-tumor vaccination is based on the existence of antigens, selectively or preferentially expressed by tumors, called tumor-associated antigens (TAAs) [12–14]. Vaccination with peptides derived from TAAs designed to stimulate specific T-cells is being a practicable approach evaluated in clinical trials [15–17]. To investigate the immune response elicited by neuritin CTL epitopes, the present study was undertaken to identify candidate CTL epitopes derived from neuritin.